Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Current and Emerging Pharmacotherapy for Fibromyalgia
Roie Tzadok
*
,
Jacob N. Ablin
*
Corresponding author for this work
Clinical Departments
Internal Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
72
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Current and Emerging Pharmacotherapy for Fibromyalgia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Fibromyalgia
100%
Emerging Pharmacotherapy
100%
Pharmacological Therapy
50%
Brain Regions
25%
Information Processing
25%
Cannabinoids
25%
Clinical Experience
25%
Opioids
25%
Memory Impairment
25%
Alertness
25%
Psychological Disorders
25%
Cognitive Dysfunction
25%
Expert Opinion
25%
Area Cover
25%
Somatic Symptoms
25%
Integrative Approach
25%
Conditioned Pain Modulation
25%
Pain Processing
25%
Tailor-made
25%
Duloxetine
25%
FDA-approved Drugs
25%
CNS Disorders
25%
Functional Imaging
25%
Pain Disorder
25%
Prevalence Estimation
25%
Genetic Imaging
25%
Pregabalin
25%
Milnacipran
25%
Pain Cognitions
25%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacotherapy
100%
Fibromyalgia
100%
Syndrome
75%
Prevalence
25%
Cognitive Defect
25%
Duloxetine
25%
Memory Disorder
25%
Psychogenic Pain
25%
Pregabalin
25%
Milnacipran
25%
Cannabinoid
25%
Mental Diseases
25%